AVITA Medical Inc

AVITA Medical operates with a market capitalization of $134.19 million and a price-to-book ratio of 4.12, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by $16.95 million in cash and equivalents, but this is offset by $41.30 million in long-term debt, resulting in a negative net cash position. The current ratio of 7.25 suggests strong short-term liquidity, but the debt-to-equity ratio of 1.27 highlights a moderate leverage profile.

Profitability metrics are weak, with a return on equity of -57.29% and a return on assets of -19.16%, both significantly below industry norms. The company reported a net loss of $18.66 million and an operating loss of $17.21 million, reflecting ongoing operational challenges. Gross profit of $9.67 million was insufficient to cover operating expenses, indicating a need for cost optimization or revenue growth.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the ability to offset performance shortfalls in one area with gains in another.

Looking ahead, AVITA Medical is projected to maintain a negative growth trajectory, with no significant revenue increases expected in the current or next fiscal year. The company's operating cash flow of -$20.86 million and free cash flow of -$19.60 million underscore the need for external financing or operational improvements to sustain operations.

The risk assessment indicates a medium liquidity risk due to the negative net cash position and a low dilution risk, as the company has not issued additional shares recently. However, the ongoing net losses and high debt levels could necessitate future equity or debt financing, which may dilute existing shareholders.

Recent filings and transcripts have not disclosed any material events that would significantly alter the company's risk profile or strategic direction. The company remains focused on its pipeline of cell therapy products, but no recent clinical or regulatory milestones have been reported that would suggest a near-term commercial breakthrough.

AVITA Medical Inc (RCEL.O) has entered the scope of active monitoring, marking the first analysis for this ticker with no prior basis for delta computation. This initial assessment establishes a baseline for the company, which currently maintains a profile characterized by zero officers, two analysts, and no index memberships, while being held by 18 top holders. The most material signal detected is a notable addition to the holder list. As of March 31, 2026, investor ID 931 added 1,289 shares to their position. This acquisition represents a portfolio weight of approximately 2.37e-06 percent and a total value of $0.004924 million. This activity was detected on June 20, 2026, providing the first concrete data point regarding institutional or significant holder interest in the stock. Given the absence of prior material changes, this new holding serves as the primary indicator of recent capital movement for the company. The significance of this change lies in its role as the foundational data point for future tracking. With only two analysts covering the stock and no index memberships, shifts in holder composition, such as the entry of investor ID 931, offer early visibility into potential changes in market sentiment or liquidity dynamics for AVITA Medical.

Analysts project 25.7% upside to a mean price target of $6.40, reflecting a consensus buy recommendation from six analysts.

Operating and net margins exceed the biotechnology cohort median, indicating relatively better profitability efficiency despite ongoing losses.

Cash conversion metrics rank above the cohort median, suggesting efficient management of cash flows relative to peers.

Revenue growth trajectory shows improvement from FY-3 to FY0, with FY0 revenue reaching $71.6 million.

Dilution risk is assessed as low, providing some protection to existing shareholders against immediate equity erosion.

The company faces high credit risk and carries a high leverage band with a negative debt-to-equity ratio.

Free cash flow deteriorated significantly to -$69.9 million in FY-1, highlighting severe cash burn and liquidity pressures.

Return on equity and return on assets remain deeply negative, underperforming the biotechnology cohort median significantly.

The current ratio of 0.57 indicates potential short-term liquidity issues, as current assets do not cover current liabilities.

Debt-to-equity ratio ranks in the bottom quartile of the cohort, signaling excessive leverage compared to peers.

Revenue $17.6M, −4,3% YoY; Operating income −4,5% YoY.

• ▍Revenue $17.6M, −4,3% YoY
• ▍Operating income −4,5% YoY
• ▍Net income −0,3% YoY
• ▍Free cash flow +14,9% YoY
• ▍Net margin -66.0%

Revenue $17.1M, −12,7% YoY; Operating income +33,7% YoY.

• ▍Revenue $17.1M, −12,7% YoY
• ▍Operating income +33,7% YoY
• ▍Net income +18,6% YoY
• ▍Free cash flow +31,1% YoY
• ▍Net margin -77.3%

Revenue $18.4M, +21,2% YoY; Operating income +28,6% YoY.

• ▍Revenue $18.4M, +21,2% YoY
• ▍Operating income +28,6% YoY
• ▍Net income +35,6% YoY
• ▍Free cash flow +44,5% YoY
• ▍Net margin -53.9%

Revenue $18.5M, +66,7% YoY; Operating income +31,3% YoY.

• ▍Revenue $18.5M, +66,7% YoY
• ▍Operating income +31,3% YoY
• ▍Net income +25,7% YoY
• ▍Free cash flow +30,8% YoY
• ▍Net margin -74.9%

Revenue $18.4M; Operating income -$10.0M.

• ▍Revenue $18.4M
• ▍Operating income -$10.0M
• ▍Net margin -63.0%

Revenue $19.5M; Operating income -$13.8M.

• ▍Revenue $19.5M
• ▍Operating income -$13.8M
• ▍Net margin -82.9%

Revenue $15.2M; Operating income -$15.6M.

• ▍Revenue $15.2M
• ▍Operating income -$15.6M
• ▍Net margin -101.3%

Revenue $11.1M; Operating income -$17.2M.

• ▍Revenue $11.1M
• ▍Operating income -$17.2M
• ▍Net margin -168.0%

Revenue $71.6M, +11,4% YoY; Operating income +24,8% YoY.

• ▍Revenue $71.6M, +11,4% YoY
• ▍Operating income +24,8% YoY
• ▍Net income +21,4% YoY
• ▍Free cash flow +31,3% YoY
• ▍Net margin -67.8%

Revenue $64.3M, +28,1% YoY; Operating income −32,7% YoY.

• ▍Revenue $64.3M, +28,1% YoY
• ▍Operating income −32,7% YoY
• ▍Net income −74,8% YoY
• ▍Free cash flow −93,5% YoY
• ▍Net margin -96.3%

Revenue $50.1M, +45,7% YoY; Operating income −55,1% YoY.

• ▍Revenue $50.1M, +45,7% YoY
• ▍Operating income −55,1% YoY
• ▍Net income −32,7% YoY
• ▍Free cash flow −36,1% YoY
• ▍Net margin -70.6%

Revenue $34.4M, +146,6% YoY; Operating income −90,7% YoY.

• ▍Revenue $34.4M, +146,6% YoY
• ▍Operating income −90,7% YoY
• ▍Net income −84,8% YoY
• ▍Net margin -77.5%